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Activation of Raf-1 suppresses integrin activation, po-
tentially through the activation of extracellular signal-
regulated kinases 1 and 2 (ERK1/2). However, bulk
ERK1/2 activation does not correlate with suppression.
PEA-15 reverses suppression of integrin activation and
binds ERK1/2. Here we report that PEA-15 reversal of
integrin suppression depends on its capacity to bind
ERK1/2, indicating that ERK1/2 function is indeed re-
quired for suppression. Mutations in either the death
effector domain or C-terminal tail of PEA-15 that block
ERK1/2 binding abrogated the reversal of integrin sup-
pression. Furthermore, we used ERK/p38 chimeras and
site-directed mutagenesis to identify ERK1/2 residues
required for binding PEA-15. Mutations of residues
that precede the G helix and within the mitogen-
activated protein kinase insert blocked ERK2 binding
to PEA-15, but not activation of ERK2. These ERK2
mutants blocked the ability of PEA-15 to reverse sup-
pression of integrin activation. Thus, PEA-15 regula-
tion of integrin activation depends on its binding to
ERK1/2. To directly test the role of ERK1/2 localization
in suppression, we enforced membrane association of
ERK1 and 2 by joining a membrane-targeting CAAX
box sequence to them. Both ERK1-CAAX and ERK2-
CAAX were membrane-localized and suppressed inte-
grin activation. In contrast to suppression by mem-
brane-targeted Raf-CAAX, suppression by ERK1/2-
CAAX was not reversed by PEA-15. Thus, ERK1/2 are
the Raf effectors for suppression of integrin activa-
tion, and PEA-15 reverses suppression by binding
ERK1/2.
Changes in integrin affinity for ligand (activation) play a
central role in integrin functions such as cell adhesion, migra-
tion and assembly of the extracellular matrix (1). Activation is
transduced by a complex series of cellular signaling pathways
that modify the interaction of cytoplasmic proteins, such as
talin (2), with integrin cytoplasmic domains (3). Integrin acti-
vation is a tightly regulated event, suggesting the existence of
pathways that can both promote and suppress integrin activa-
tion. One such pathway leads to a marked reduction in integrin
affinity as a consequence of activation of the small GTP-bind-
ing protein H-Ras and its downstream effector kinase Raf-1 (4).
Inhibition of extracellular signal-regulated kinases 1 and 2
(ERK1/2)1 by the phosphatase MKP-1 (4) but not MKP-3 (6)
reduces integrin suppression, indicating that ERK1/2 are likely
downstream effectors of H-Ras/Raf-1-mediated suppression. R-
Ras, a small GTP-binding protein with substantial homology to
H-Ras, has the opposite effect of H-Ras on the integrins (i.e.
promoting integrin activation) (5). Thus, the interplay between
R-Ras and H-Ras could act as a rheostat for integrin function.
Certain chimeras of H-Ras/R-Ras proteins that retain the abil-
ity to suppress integrin activation were weak activators of
ERK1/2 (6). Moreover, inhibition of bulk ERK1/2 activation by
use of a MEK inhibitor or transfection of MKP-3 does not
abolish suppression (6). These observations suggest that Ras-
mediated integrin suppression may be independent of ERK1/2
or that low level ERK1/2 activation in particular cellular areas
is sufficient for suppression.
Interest in further characterizing the intracellular signaling
pathways that regulate integrin activation led to the isolation
of a small protein, previously designated PEA-15 (7, 8). Cellu-
lar expression of PEA-15, a 15-kDa protein expressed in a
broad range of tissues and enriched in astrocytes (9), prevents
activated H-Ras/Raf-1-mediated integrin suppression (8).
PEA-15 binds ERK1/2 but does not inhibit ERK1/2 kinase
activity or activation; instead, PEA-15 redirects the output of
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ERK1/2 signaling by altering the subcellular localization of
ERK1/2 (10). Thus, it is plausible that PEA-15 may be one of a
class of proteins capable of modulating ERK1/2 function and
thereby integrin suppression. PEA-15 is composed of an N-
terminal death effector domain (DED), a protein interaction
module more commonly found in proteins that regulate apopto-
sis, and a C-terminal tail of irregular structure. NMR “foot-
printing” and mutagenesis studies identified residues in both
the DED and tail that are required for ERK1/2 binding (11). In
this study, we explored the relationship between PEA-15 inter-
action with ERK1/2 and the role of ERK1/2 in integrin suppres-
sion. Single point mutations in either the DED or tail of PEA-
15, which inhibit interaction with ERK1/2, resulted in a
concomitant loss of the ability of PEA-15 to reverse suppression
of integrin activation. Furthermore, we used a series of ERK/
p38 chimeras (12, 13) in combination with site-directed mu-
tagenesis to identify ERK1/2 residues required for PEA-15
binding. Point mutation of residues preceding the G helix or
within the MAPK insert blocked the capacity of ERK2 to bind
PEA-15 but did not adversely effect ERK2 phosphorylation.
Cellular expression of each of these mutant ERKs blocked the
ability of PEA-15 to reverse suppression of integrin activation.
Thus, the capacity of PEA-15 to regulate integrin activation
depends on its binding to ERK1/2. To directly test the role of
ERK1/2 in suppression, we enforced membrane association of
ERK1 and 2 by joining a membrane-targeting CAAX box se-
quence to them. Both ERK1-CAAX and ERK2-CAAX were
membrane-localized and suppressed integrin activation. In
contrast to suppression by membrane-targeted Raf-CAAX, sup-
pression by ERK1/2-CAAX was not reversed by PEA-15. Thus,
ERK1/2 are the Raf effectors that lead to suppression of inte-
grin activation, and PEA-15 reverses suppression by binding
ERK1/2.
MATERIALS AND METHODS
Cell Culture—Chinese hamster ovary (CHO) cells were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with
10% fetal calf serum (Invitrogen), 1% nonessential amino acids (Sigma),
1% glutamine (Sigma), and 1% penicillin and streptomycin (Sigma).
Antibodies, Reagents, and cDNA Constructs—The activating 1 an-
tibody 9EG7 was purchased from Pharmingen. The anti-ERK1 and
anti-ERK2, anti-Ras, anti-RhoGDi, and anti-phospho-ERK1/2 antibod-
ies were purchased from Santa Cruz Biotechnology, Inc. The mouse
monoclonal anti-HA antibody (12CA5) and anti-integrin 1 (7E2) were
as described (4). Anti-lamin A/C was a generous gift from Dr. Larry
Gerace (The Scripps Research Institute). Anti-PEA-15 (3099) was pre-
viously described (14). All PEA-15 mutants were generated by using the
QuikChange kit (Stratagene) using HA-PEA-15-pcDNA3 as template.
ERK2 mutants were generated by the same strategy using
HA-ERK2-pcDNA3 as template. All constructs were confirmed by DNA
sequencing. The p38/ERK1 chimeric constructs have been described
(12). The p38/ERK2 constructs were gifts from Dr. Melanie Cobb (13).
The HA-ERK1-CAAX-pEF and HA-ERK1-SAAX-pEF constructs were
as described (15). Kinase-dead HA-ERK1(K71R)-CAAX-pEF was
generated by using the QuikChangeTM kit (Stratagene) using
HA-ERK1-CAAX-pEF as template. GST-PEA-15 expression vector was
constructed by subcloning the full-length PEA-15 from HA--PEA-15-
pcDNA3 into the pGEX-2T vector (Amersham Biosciences). Purification
of recombinant 3Fn-(9–11) from the pGEX expression vector encoding
Type III repeats 9–11 of fibronectin was previously described (16).
In Vitro PEA-15 Pull-down Assay—CHO cells were transfected with
p38/ERK1/2 chimeras using LipofectAMINE reagents as per the man-
ufacturer’s protocol (Invitrogen). 40–48 h post-transfection, cells were
washed with 1 phosphate-buffered saline (pH 7.4) and lysed in lysis
buffer (20 mM HEPES, pH 7.2, 2 mM MgCl2, 2 mM EGTA, and 1 mM
phenylmethylsulfonyl fluoride). Total lysates were homogenized with
binding buffer (20 mM HEPES, pH 7.2, 1% Nonidet P-40, 10% glycerol,
2 mM EGTA, 2 mM MgCl2) and centrifuged at 12,000 rpm for 10 min.
The cleared lysates (supernatant) were mixed with 10 l of GSH-
Sepharose-bound GST-PEA-15 for 2 h at 4 °C. After washing four
times with binding buffer, bound proteins were eluted with SDS
sample buffer and resolved by SDS-PAGE under reducing conditions.
FIG. 1. PEA-15 regulates integrin activation. A, PEA-15 null (KO) or wild type (WT) mouse fibroblasts were incubated at room temperature
for 30 min in the presence or absence of TPA (100 nM). The cells were suspended, and the binding of 3Fn-(9–11) was assayed by two-color flow
cytometry as described under “Materials and Methods.” In the left panel, TPA elicited an increase in 3Fn-(9–11) binding in wild type cells but not
in the null cells. However, when the cells were transfected with PEA-15, both null and wild type exhibited similarly enhanced 3Fn-(9–11) binding
in response to TPA (right panel). B, cell lysates from the untransfected cells in A were fractionated by SDS-PAGE and immunoblotted (IB) with
antibodies against phospho-ERK (pERK) or total ERK. Note the similar degrees of TPA-induced phosphorylation of ERK in the wild type and null
cells. C, the cell lysates from A were immunoblotted for the expression of the HA epitope to verify similar quantities of recombinant PEA15
expression in all of the transfected cell preparations.
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Bound proteins were visualized by Western blotting with anti-HA to
detect transfected chimeric proteins. The same protocol was used for
GST-PEA-15 pull-down of HA-ERK1-CAAX, HA-ERK1-SAAX, and
HA-ERK1(K71R)-CAAX.
Wild-type and mutant ERK2 contained in a NpT7–5 vector (17) were
expressed in vitro using the TNT T7 coupled reticulocyte lysate system
(Promega) in the presence of [35S]methionine. GST-PEA-15 bound to
glutathione-agarose beads (Sigma) was incubated with 35S-labeled
wild-type and mutant ERK2 proteins in 150 l of 50 mM HEPES (pH
7.4), 50 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and 10% glycerol.
Samples were incubated for 2 h at 4 °C and then washed three times
with 0.5 ml of the same buffer. The bound proteins were separated on
16% Tris-Tricine gels and visualized by phosphorimaging.
Flow Cytometry—Analytical two-color flow cytometry was carried
out as previously described (4). Briefly, CHO cells were transfected with
GFP (0.1 g) as transfection marker and a combination of HA-ERK2-
pcDNA3, ERK2 mutants in the pcDNA3 vector, H-Ras(G12V)-pcDNA3,
and HA-PEA-15-pcDNA3. A total of 5 g of DNA was used for each
transfection. Transient transfections were carried out using Lipo-
fectAMINE Plus reagent as per the manufacturer’s protocol (Invitro-
gen). 24 h post-transfection, cells were harvested and analyzed for
transfection efficiency (GFP) and integrin binding to 3Fn-(9–11). In
FIG. 2. PEA-15 reversal of
H-Ras(G12V) suppression requires
residues implicated in ERK1/2 bind-
ing. A, ribbon representation of the three-
dimensional structure of PEA-15 (10)
(Protein Data Bank accession code 1N3K)
with helices colored in yellow and the
loops and C-terminal tail in gray. The side
chains of selected residues are drawn as
ball-and-stick models with Asp74, Ile121,
Leu123, and Lys129 shown in red, Lys122 in
pink, and Glu18 in green. B, summary of
FACS analysis of the effect of point mu-
tations on the ability of PEA-15 to rescue
H-Ras-induced suppression. To measure
reversal of suppression, various PEA-15
mutants were transfected with wild-type
ERK2 and H-Ras(G12V). Percentage re-
versal is calculated as described under
“Materials and Methods.” Mutations of
PEA-15 that block ERK1/2 binding
(I121R, L123R, and K129E) abolish rever-
sal. In contrast, mutants that partially
inhibit ERK1/2 binding either partially
reduce (K122E) or fail to reduce (E18R)
reversal. C, each of the transfected cells
from B were lysed in SDS sample buffer
and fractionated by SDS-PAGE, and the
expression of wild-type or mutant PEA-15
was assessed by immunoblotting. Blot-
ting with anti-phospho-ERK1/2 is shown
in the lower panel. Note that neither wild
type nor mutant PEA-15 reduces the ex-
tent of ERK1/2 phosphorylation induced
by H-Ras(G12V).
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brief, for each transfection, harvested cells were divided into three
tubes. The three preparations were used to assay for binding to 3Fn-
(9–11) alone, binding in the presence of EDTA (10 mM), or in the
presence of 9EG7 (10 ng/l). All incubation and washes were carried out
using 1 Tyrode buffer (10 mM HEPES, 10 g of NaCl, 1.015 g of
NaHCO3, 0.195 g of KCl, 1 mg/ml dextrose, 1 mg/ml bovine serum
albumin, 1 mM CaCl2, 1 mM MgCl2, pH 7.4). Cells were first incubated
with EDTA or 9EG7 for 10 min at room temperature, and 3Fn-(9–11)
was then added to all samples and allowed to incubate at room tem-
perature for 20 min. After washing twice with 1 Tyrode buffer, cells
were incubated with streptavidin-R-phycoerythrin (20 ng/l) on ice for
20 min. Propidium iodide (1 ng/l) was added to each sample for the last
5 min. Samples were washed twice before analysis. Integrin activation
was quantified as an activation index (AI) as previously defined (4).
AI  100 * (F  Fo)/(Fm  Fo), where F represents the geometric mean
fluorescence (GMF) of 3Fn-(9–11) binding alone, Fo is the GMF of
3Fn-(9–11) binding in the presence of EDTA(10 mM), and Fm is the
GMF of 3Fn-(9–11) binding in the presence of 9EG7. The percentage of
suppression was calculated as 100 * (AIM  AIT)/AIM, where AIM is the
activation index of the mock-transfected cells, and AIT is the activation
index in the presence of a transfected cDNA. The percentage of reversal
of suppression was calculated as 100 * (AI  AIR)/AI, in which AI is the
activation index of the control cells, and AIR is the activation index in
the presence of a transfected rescuing cDNA. In addition to FACS
analysis, the cell lysate of each transfection was analyzed for expres-
sion of the transfected constructs and phosphorylation of ERK1/2 by
immunoblotting. The same protocol was used to assay integrin sup-
pression by Raf-CAAX, HA-ERK1-CAAX, HA-ERK1-SAAX, and
HA-ERK1(K71R)-CAAX.
PEA-15 Knockout Fibroblasts—PEA-15 knockout fibroblasts derived
from PEA-15 null mice (18) or wild-type fibroblasts were transiently
transfected with cDNA encoding a reporter, GFP (0.3 g), and HA
PEA-15-pcDNA3 (3 g). As a control, knockout and wild-type fibro-
blasts were transiently transfected with GFP and empty pcDNA3 vec-
tor. Transient transfections were carried out using LipofectAMINE and
Plus reagents per the manufacturer’s protocol (Invitrogen). 24 h post-
transfection, cells were incubated in 0.5% serum Dulbecco’s modified
Eagle’s medium overnight. After stimulation with 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (100 nM) for 1 h, cells were harvested and
analyzed for transfection efficiency (GFP) and integrin binding to 3Fn-
(9–11) by two-color flow cytometry as described above. Additionally, cell
lysates were analyzed for expression of transfected HA-PEA-15 and
phosphorylation of ERK1/2 induced by TPA treatment.
Subcellular Fractionation—CHO cells were transfected as described
above with HA-ERK1-CAAX, HA-ERK1-SAAX, or HA-ERK1(K71R)-
CAAX. 24 h post-transfection, cells were harvested in 0.5 ml of lysis
buffer (20 mM HEPES-KOH, pH 7.5, 1.5 mM MgCl2, 5 mM KCl, 0.2 mM
NaVO4, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 mM phenylmethyl-
sulfonyl fluoride). After a 10-min incubation on ice to allow for swelling,
cells were disrupted using 40 strokes in a Dounce homogenizer. A
fraction of the total cell lysate was saved prior to centrifugation at 2000
rpm for 10 min to pellet the nuclei. The supernatant was subjected to
additional centrifugation at 13,000 rpm for 30 min to pellet the mem-
brane fraction. The resultant supernatant is the cytosolic fraction. The
membrane pellet was extracted at 4 °C with lysis buffer containing 1%
Nonidet P-40. After centrifuging at 14,000 rpm for 10 min, the mem-
brane-soluble supernatant was removed, and the insoluble pellet was
resuspended in 100 l of 1 SDS-PAGE buffer. Total lysate, mem-
brane-soluble, and cytosolic fractions were analyzed for protein expres-
sion by immunoblot.
FIG. 3. PEA-15 binding to ERK/p38 chimeras. A, schematic representation of ERK/p38 chimeras. MAPKs are composed of 12 conserved
subdomains; the N-terminal domain comprises kinase subdomains I–IV together with the C-terminal loop, and the C-terminal domain includes
kinase subdomains V–XI (also see Fig. 4A). Sequence derived from ERK1/2 and p38 are represented by white and gray boxes, respectively. The
chimeras are named according to the subdomains that were exchanged (12, 13). Chimera PIVE contains p38 sequence constituting the N terminus
up to and including subdomain IV with the remaining sequence from ERK2. Chimera PIVECTP is similar to PIVE except that it also contains the
C-terminal loop of p38. Chimeras EVIIP, EVIIIP, and EXIP comprise N-terminal ERK1 sequence up to and including subdomain VII, VIII, and
XI, respectively, with p38 sequence constituting the remaining C terminus. Chimera EVIIIPXIE is similar to EVIIIP except that it also includes
the C-terminal loop of ERK1. B and C, lysates from CHO cells transfected with each chimeric ERK/p38 construct were incubated with GST-PEA-15
fusion protein-coated beads. Bound proteins were detected by Western blotting with anti-HA. ERK1 and ERK2 bind to GST-PEA-15, whereas p38
does not. Only those chimeric ERK/p38s containing subdomains X and XI of ERK1/2, which include the MAPK insert (underlined) bind to
GST-PEA-15.
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RESULTS
Mutations of PEA-15 That Block ERK1/2 Binding Abrogate
Reversal of H-Ras/Raf-1-dependent Integrin Suppression—
PEA-15 binds ERK1/2 and blocks the ability of activated H-Ras
to suppress activation of recombinant chimeric integrins. To
determine whether PEA-15 affects the activation of native in-
tegrins, we assessed the effects of PEA-15 on activation of
integrins. Both wild type and PEA-15 knockout fibroblasts
bound to the recombinant cell-binding domain of fibronectin
(3Fn-(9–11); Fig. 1A) to a similar extent. In contrast, when we
stimulated integrin activation with TPA, wild type fibroblasts
showed an increase in specific 3Fn-(9–11) binding (Fig. 1A),
but the PEA-15 knockout cells (Fig. 1A) did not alter 3Fn-(9–
11) binding. The TPA was active in both cell contexts, since it
activated ERK MAPK (Fig. 1B). These data suggested the
possibility that the absence of PEA-15 rendered the integrins
resistant to activation, possibly because TPA also activated the
ERK pathway leading to concomitant suppression. To test this
possibility, we reconstituted the knockout cells with PEA-15,
leading to restoration of TPA activation of 3Fn-(9–11) binding.
In contrast, transfection of wild type cells with PEA-15 had no
additional effect on responsiveness to TPA (Fig. 1A). Compa-
rable expression of transfected HA-PEA-15 was observed (Fig.
1B) in both cell types. Thus, endogenous PEA-15 can regulate
the response of cellular integrins to agonists.
The foregoing experiment showed that PEA-15 can promote
cellular activation of integrins by agonists that activate the
ERK MAPK pathway. To directly test this idea, we utilized the
CHO cell system that has been extensively employed to analyze
integrin activation (4, 6, 8, 14, 19, 20). In these cells, 3Fn-(9–
11) binds to endogenous integrin 51, and that binding can be
suppressed by transfection with activated H-Ras or Raf mu-
tants (6). Co-transfection with PEA-15 prevented activated
H-Ras(G12V) suppression of 3Fn-(9–11) binding (data not
shown, but see Fig. 2B). Thus, PEA-15 can promote the acti-
vation of endogenous integrin 51 and can prevent suppres-
sion by activated H-Ras.
To explore the role of the PEA-15 interaction with ERK1/2 in
modulating integrin activation, we exploited the recently de-
termined structure of PEA-15 (11). PEA-15 consists of an N-
terminal DED composed of six antiparallel amphipathic -hel-
ices closely packed around a central hydrophobic core, followed
by a long C-terminal tail (Fig. 2A). The C-terminal tail is
irregularly structured with the exception of residues 120–123,
which form a single turn of 310-helix. NMR “footprinting” and
site-directed mutagenesis have established that residues in
both the DED and the tail are involved in ERK1/2 binding (10,
11). In particular, one mutation in the DED (D74A) and three
mutations in the tail (I121R, L123R, and K129E) strongly
inhibit binding to ERK1/2. The D74A mutant has previously
FIG. 4. Identification of candidate
ERK2 point mutations that abrogate
PEA-15 binding. A, ribbon representa-
tion of the three-dimensional structure of
unphosphorylated ERK2 (24) with
-strands colored in green, helices in yel-
low, and the MAPK insert in white. The
G helix and the 1L14 and 2L14 heli-
ces of the MAPK insert are labeled and
indicated by a dashed square. B, sequence
alignment of the G helix and MAPK in-
sert regions of rat ERK2, rat ERK1, and
mouse p38. Secondary structure ele-
ments identified in ERK2 (24) are shown
above the sequences.
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been shown to block the effects of PEA-15 on integrin activation
(8). Similarly, each of the three new mutants that block ERK1/2
binding also abrogated the effects of PEA-15 on integrin acti-
vation (Fig. 2B). Mutations within PEA-15 that were only par-
tially defective for ERK1/2 binding (11) either partially
(K122E) or fully (E18R) reversed integrin suppression, which
correlates with the relative defect in PEA-15/ERK2 interaction
(11) (Fig. 2B). These observations were not a consequence of
differential expression levels of the mutants (Fig. 2C). Further-
more, ERK1/2 was phosphorylated when each of the mutants
was co-transfected with H-Ras(G12V) (Fig. 2C). Thus, the ca-
pacity of PEA-15 to bind to ERK1/2 closely correlates with its
ability to reverse H-Ras suppression of integrin activation.
Identification of ERK1/2 Mutants That Fail to Bind PEA-
15—The foregoing experiments showed that PEA-15 mutations
that strongly inhibit ERK1/2 binding also abrogated the capac-
ity of PEA-15 to block suppression of integrin activation. How-
ever, these mutations may perturb other functions of PEA-15
in addition to ERK1/2 binding. To exclude this possibility, we
sought to identify mutations in ERK1/2 that disrupt PEA-15
binding and to learn whether they block the effect of PEA-15 on
integrin activation. PEA-15 binds specifically to ERK1/2 and
not to the related MAPKs p38 or c-Jun N-terminal kinase (10).
Furthermore, there is a high degree of sequence identity be-
tween ERK1 and ERK2. To map the regions of ERK1/2 involved
in PEA-15 binding, we employed a number of existing ERK/p38
chimeras (Fig. 3A) used previously to identify domains impor-
tant for interacting with upstream kinases, target substrates,
and phosphatases (12, 13, 21). The three-dimensional struc-
tures of ERK1/2 and p38 are similar (22), and the chimeras
contain selected intact structural subdomains from each en-
zyme. Binding to PEA-15 was assessed using lysates from CHO
cells transfected with HA-tagged ERK/p38 chimeras incubated
with immobilized GST-PEA-15 (Fig. 3, B and C). A chimera
possessing the first four subdomains and the C-terminal loop of
p38, which form the N-terminal half of the protein, retained the
ability to bind PEA-15 (chimera PIVECTP in Fig. 3B). In con-
trast, studies of C-terminal chimeras of ERK1 and p38 indi-
cated that only a chimera containing subdomains X and XI of
ERK1 (chimera EXIP in Fig. 3C) retained binding activity.
Conversely, insertion of subdomains X and XI of p38 into ERK1
abolished binding (chimera EVIIIPXIE in Fig. 3C). These data
indicate that regions localized within the C-terminal domain of
ERK, subdomains X and XI in particular, are required for
PEA-15 binding.
ERK1/2 have a characteristic protein kinase structure with
an N-terminal domain rich in -sheet and a C-terminal domain
that is mostly -helical (23, 24). Structural features unique to
MAPK are an insertion of 30 residues between subdomains X
and XI and a C-terminal extension that folds back over the
N-terminal domain such that the N and C termini are in close
proximity. Subdomains X and XI of ERK1/2 encompass the G
helix and the 1L14-2L14 loop of the MAPK insert, which
form a distinct, surface exposed region of the protein situated
below the phosphorylation lip (Fig. 4A). Furthermore, this re-
gion displays considerable sequence and structural diversity
among MAPK family members (23, 25, 26) yet is highly con-
served between ERK1 and ERK2 (Fig. 4B). Thus, this diversity
could account for the failure of p38 and c-Jun N-terminal ki-
nase to bind to PEA-15. A series of point mutations were
introduced into the G helix and MAPK insert of ERK2 to
further investigate the importance of this region for the inter-
action with PEA-15. Mutations at five positions, Lys229, Tyr231,
Leu232, Lys257, and Arg259, substantially reduced or abrogated
binding to PEA-15 (Fig. 5A). These residues are located at the
start of the G helix and in the 2L14 helix of the MAPK insert
(Fig. 5B). Alteration of residues in the 1L14 helix (Asn251), in
the 1L14-2L14 loop (Ile254 and Leu256), and at the end of the
2L14 helix (Asn260, Leu263, and His267) had no effect on bind-
ing to PEA-15 (Fig. 5A and data not shown). This localizes part
of the PEA-15 binding site to the loop preceding and start of the
G helix and to the beginning of the 2L14 helix within the
MAPK insert (Fig. 5B). An essential role for this region of
ERK2 has also recently been demonstrated for the interaction
with its upstream activators, MEK1/2 (27).
ERK2 Mutants That Fail to Bind PEA-15 Block PEA-15
Reversal of Integrin Suppression—As described above, we iden-
tified several point mutations in ERK2 that blocked binding to
PEA-15. Transfection of cells with wild-type ERK2 or any of the
mutants failed to suppress or enhance the binding of 3Fn-(9–
11) to CHO cells, although all of the mutants were well ex-
pressed (Fig. 6). Furthermore, when these mutants were co-
transfected with H-Ras(G12V), they failed to enhance or
reverse suppression (Fig. 7). Moreover, each of the mutants
was phosphorylated to a similar extent to wild-type ERK2 and
did not interfere with the phosphorylation of endogenous
ERK1/2 (data not shown). Thus, expression of these ERK2
mutants neither suppressed integrin activation; nor did they
influence the ability of activated H-Ras to suppress it.
We then examined the effect of these ERK2 mutants on the
FIG. 5. Identification of ERK2 point mutations that disrupt
PEA-15 binding. A, effects of point mutations of ERK2 on interaction
with PEA-15, determined by the binding activity of [35S]methionine-
labeled wild-type (WT) or mutant ERK2 to GST-PEA-15. The Input lane
represents 10% of the total protein added to the GST-PEA-15-coated
beads. B, structure of a PEA-15 binding region of ERK2. The side chains
of residues important for PEA-15 binding are drawn as ball-and-stick
models with Tyr231, Leu232, and Lys257 shown in red and Lys229 and
Arg259 in pink.
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capacity of PEA-15 to regulate activation of integrin 51.
Expression of the mutants that failed to bind PEA-15 (ERK2
Y231E, L232E, or K257E) completely prevented PEA-15 rever-
sal of H-Ras suppression (Fig. 8A). In contrast, ERK2 bearing
mutations that weakly inhibited PEA-15 binding (e.g. K229E)
only partially reversed the effect of PEA-15. Expression of
wild-type ERK2 or of a mutant with intact PEA-15 binding did
not modify the effects of PEA-15 on integrin activation. Impor-
tantly, none of the ERK2 mutants changed the expression of
H-Ras(G12V), endogenous ERK1/2, or PEA-15 (Fig. 8B). In
addition, these mutants were phosphorylated and did not con-
sistently alter the phosphorylation of endogenous ERK2 in the
cells co-transfected with H-Ras(G12V) and PEA-15 (Fig. 8B).
Thus, expression of PEA-15 binding-defective mutants of ERK2
abolished the capacity of PEA-15 to reverse suppression of
integrin activation, confirming that PEA-15 and ERK1/2 inter-
act directly to modulate integrin function.
Membrane-targeted ERK1/2 Suppresses Integrin Activa-
tion—PEA-15 binding to ERK1/2 prevents the nuclear localiza-
tion of the activated kinases (10), suggesting that PEA-15
might reverse integrin suppression by changing the cellular
localization of ERK1/2. To test this idea, we examined the
effects of enforcing a membrane localization of ERK1/2 on
integrin activity. Transfection of cells with a chimera of the
membrane-targeting sequence of H-Ras with ERK1 (ERK1-
CAAX) resulted in profound suppression of integrin activation
(Fig. 9A) and membrane localization of the ERK1 (Fig. 9C).
Membrane localization was responsible for this effect, since a
Ser substitution for the Cys of the CAAX box (ERK1-SAAX)
was neither membrane-localized (Fig. 9C) nor suppressive (Fig.
9A). Integrin suppression required the kinase function of
ERK1, since an ERK1(K71R)-CAAX construct, which lacks ki-
nase activity, was much less suppressive (Fig. 9A) although it
was membrane-localized (Fig. 9C). All three constructs were
expressed at similar levels (Fig. 9B), and a corresponding series
of ERK2 constructs showed identical effects on integrins to the
ERK1 constructs (data not shown). Thus, membrane localiza-
tion or ERK1/2 leads to suppression of integrin activation.
PEA-15 Fails to Reverse Suppression Mediated by ERK1-
CAAX—Because enforced membrane localization of ERK1/2 led
to suppression of integrin activation and PEA-15 changes the
cellular localization of ERK 1/2, PEA-15 might reverse suppres-
sion by displacing ERK1/2 from the membrane. We were un-
able to detect enrichment of activated ERK1/2 in our bulk
membrane preparations. However, we reasoned that if the
capacity of PEA-15 to reverse suppression depended on its
ability to bind and relocalize ERK1/2, then PEA-15 should fail
FIG. 6. Expression of ERK2 mutants
has no effect on integrin activation.
A, CHO cells were transiently transfected
with expression vectors encoding GFP as
transfection reporter and the indicated
ERK2 variants. Cells were harvested and
analyzed by two-color FACS for trans-
fected cells (GFP ) and 3Fn-(9–11) bind-
ing. Shown on the ordinate is mean acti-
vation index  S.E. of three independent
experiments. A vector-transfected cell
had the same activation index as that
transfected with wild type ERK2 (data
not shown). B, expression of the ERK2
variants was assessed by immunoblotting
with anti-ERK2.
FIG. 7. Expression of ERK2 mutants has no effect on
H-Ras(G12V)-dependent integrin suppression. A, CHO cells were
transiently transfected with expression vectors encoding GFP as trans-
fection reporter, H-Ras(G12V), and the indicated ERK2 variants. Cells
were harvested and analyzed by two-color FACS for GFP expression
and 3Fn-(9–11) binding. Shown on the ordinate is mean percentage
suppression of integrin activation  S.E. from three independent ex-
periments. Transfection with wild-type or mutant ERK2 variants had
little effect on the ability of H-Ras(G12V) to induce suppression of
integrin activation. A vector-transfected cell, co-transfected with
H-Ras(G12V), exhibited the same activation index as the cell trans-
fected with wild type ERK2 and H-Ras(G12V) (data not shown). B,
ERK2 expression was assessed by immunoblotting with anti-ERK2.
Each of the mutants was well expressed.
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to reverse suppression mediated by membrane-tethered
ERK1/2. Indeed, co-transfection of PEA-15 with ERK1-CAAX
did not reverse suppression of integrin activation (Fig. 10A). In
sharp contrast, PEA-15 completely reversed suppression medi-
ated by membrane-tethered Raf-CAAX (Fig. 10A) although
PEA-15 was equally well expressed in both transfections (Fig.
10B). The ERK1-CAAX bound PEA-15 to a similar extent as
wild type ERK1 (Fig. 10C). Thus, when ERK is membrane-
tethered, PEA-15 fails to reverse suppression of integrin
activation.
DISCUSSION
Rapid modulation of ligand-binding affinity (activation) is a
central property of the integrin family of adhesion receptors
and has important functional consequences in development,
homeostasis, the immune response, and maintenance of tissue
integrity (1). The Ras family of small GTP-binding proteins and
their downstream effectors are key players in regulating inte-
grin activation. Activated H-Ras can suppress integrin activa-
tion via its downstream effector kinase, Raf-1, to control cell
morphology, migration, and assembly of the extracellular ma-
trix (4). This suppression could be mediated by the ERK1/2
MAPK pathway; however, bulk ERK1/2 activation does not
correlate with suppression (6). The small DED-containing pro-
tein, PEA-15, reverses H-Ras suppression of integrin activation
and binds to ERK1/2, altering the subcellular localization of
ERK1/2 and consequently the outcome of the ERK1/2 signaling
cascade (8, 10). Here we demonstrate that the ability of PEA-15
to reverse suppression lies in its capacity to bind ERK1/2,
indicating that ERK1/2 function is required for suppression.
Our results further suggest that reversal of suppression by
PEA-15 is due to inhibition of an ERK1/2 function, possibly by
preventing access to membrane-associated substrates, rather
than the acquisition of integrin-activating functions by the
PEA-15-ERK1/2 complex.
The recently determined three-dimensional structure and
mutational analysis of PEA-15 indicated the presence of two
distinct binding sites for ERK, an acidic patch within the DED
and a positively charged region within the C-terminal tail (11).
Point mutations of individual residues in either of these re-
gions of PEA-15 are sufficient to abrogate ERK1/2 binding and
resulted in a loss of the capacity of PEA-15 to reverse H-Ras/
Raf-1-dependent integrin suppression. Mutations in the C-ter-
minal tail that block ERK1/2 binding (I121R, L123R, and
K129E) also block PEA-15 reversal of integrin suppression, as
previously observed for the D74A mutant in the DED (8).
Mutations within PEA-15 that exhibited reduced ERK1/2 bind-
ing retained partial ability to reverse H-Ras suppression
(K122E) or fully reversed suppression (E18R). These results
correlate with the relative ability of these mutants to inhibit
the ERK-stimulated transcription of Elk-1 (10, 11) and rein-
force the functional importance of both the DED and C-termi-
nal tail of PEA-15.
An analysis of ERK/p38 chimeras and ERK1/2 mutants pin-
pointed residues within the G helix and MAPK insert as
critical for both PEA-15 binding and reversal of integrin sup-
pression. Mutations at five positions, Lys229, Tyr231, Leu232,
FIG. 8. Expression of ERK2 mutants
that do not bind PEA-15 abolishes
PEA-15 reversal of integrin suppres-
sion. A, CHO cells were transiently
transfected with expression vectors en-
coding GFP as transfection reporter,
H-Ras(G12V), PEA-15, and the indicated
ERK2 variants. Cells were harvested and
analyzed by two-color FACS for GFP ex-
pression and 3Fn-(9–11) binding. Shown
on the ordinate is mean percentage rever-
sal of suppression  S.E. from three inde-
pendent experiments. ERK2 mutants
that are lacking PEA-15 binding function
(Y231E, L232E, and K257E) eliminated
PEA-15 reversal of suppression. ERK2
mutants that exhibited a partial decrease
in PEA-15 binding (K229D and R259E)
showed decreased PEA-15-mediated re-
versal of integrin binding. B, cell lysates
from the experiment described in A were
fractionated by SDS-PAGE, and immuno-
blots were probed for ERK2, phospho-
ERK1/2 (pERK), and the HA tag (HA).
Note that phospho-ERK staining corre-
lated with ERK expression of endogenous
and transfected ERK2. The ERK2 muta-
tions that block reversal (i.e. result in in-
creased suppression of integrin activation)
do not increase the phosphorylation of en-
dogenous ERK2. The lower panel illustrates
similar H-Ras(G12V) and PEA-15 expres-
sion in each cell lysate.
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Lys257, and Arg259, substantially reduced or abrogated binding
to PEA-15. Cellular expression of each of these ERK2 mutants
blocked the ability of PEA-15 to reverse suppression of integrin
activation. In the crystal structure of unphosphorylated ERK2,
the activation loop extends from the active site and folds down
upon the C-terminal domain, making contacts with residues
from both the N terminus of helix G and the MAPK insert
(24). Although the mutations described here are located on the
same surface of ERK2 as the active site, and residues Tyr231
and Leu232 are in close proximity to the activation loop, they
have no adverse effect on ERK2 activation. Each of the mutants
was expressed at level comparable with wild-type ERK2 and
was phosphorylated to a similar extent, indicating that the
mutants were correctly folded and able to serve as a substrate
for MEK1/2. Importantly, these mutants blocked the effect of
PEA-15 in the presence of endogenous wild-type ERK1/2. This
implies that the mechanism of action of PEA-15 on integrins
involves loss of ERK1/2 function rather than a novel function
acquired by the PEA-15-ERK1/2 complex.
Several regions of MAPKs have been implicated in interac-
tions with their substrates, activators, and regulators. A com-
mon docking groove has been identified in the C-terminal do-
main that functions as a general binding site (28–31) for many
proteins that contain a conserved docking site sequence (32).
This docking groove contains an acidic patch termed the CD
domain (29) and adjacent hydrophobic patches (28) that accom-
modate the basic and hydrophobic motifs of the docking site
sequences. However, this docking groove does not appear to
play a role in the interaction with PEA-15, since ERK1/2 mu-
tants that have been shown to abrogate binding by substrates
and activators of ERK1/2 (T157E, T158D, D316N, and D319N)
(29, 30) had no effect on PEA-15 binding (data not shown).
These findings are consistent with the absence of a conserved
docking site sequence within PEA-15. In contrast, recognition
of the G helix and MAPK insert of ERK1/2 by PEA-15 and
MEK1/2 (27) highlights this region as a potential second com-
mon docking site. In addition to MAPKs, insertions in the
kinase core between subdomains X and XI are found in the
cyclin-dependent kinases and glycogen synthase kinase-3. X-
ray crystal structures of cyclin-dependent kinase 2 and glyco-
gen synthase kinase-3 in complex with their regulatory factors
have also recently demonstrated the functional importance of
this region for these kinase families (33–35). Thus, the inser-
tion in MAPKs and other structurally related serine/threonine
kinases may act as a common docking site for a variety of
regulatory proteins.
The dominant feature of the ERK1/2 binding surface of
PEA-15 is the presence of two loci of opposite charge. The
binding epitope within the PEA-15 DED is predominantly
negatively charged, whereas the binding surface in the C-
FIG. 9. Expression of membrane-
targeted ERK1 induces integrin sup-
pression. A, CHO cells were transfected
with plasmids encoding membrane-tar-
geted ERK1-CAAX, kinase-dead ERK1
(K71R)-CAAX, and nontargeted ERK1-
SAAX. After 48 h, the cells were
suspended, and 3Fn-(9–11) binding and
percentage suppression were assessed as
described under “Materials and Meth-
ods.” Membrane targeting of ERK1 in-
duces suppression, whereas nontargeted
SAAX construct did not. This suppression
is dependent on the kinase activity of
ERK1, since the kinase-dead K71R
ERK1-CAAX exhibits diminished ability
to suppress. B, lysates from each transfec-
tion were fractionated by SDS-PAGE, and
expression of each ERK construct was an-
alyzed by immunoblotting with anti-HA.
C, cells from each transfection were dis-
rupted in a Dounce homogenizer, and the
resulting lysate was subjected to differen-
tial centrifugation as described under
“Materials and Methods.” Total lysate,
membrane, and cytosolic fractions were
analyzed by immunoblotting. The iden-
tity and purity of the subcellular fractions
were assessed by blotting with a mem-
brane marker (integrin 1), cytosolic
marker (RhoGDi), and nuclear marker
(lamin A/C). In addition, each fraction
was blotted with anti-HA to ascertain the
subcellular location of each transfected
construct. ERK1-CAAX and ERK1
(K71R)-CAAX were enriched in the mem-
brane, whereas ERK1-SAAX was primar-
ily in the cytosol. Representative images
from one experiment; lanes were rear-
ranged for clarity.
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terminal tail is composed of hydrophobic and positively
charged residues (11). Thus, it is tempting to speculate that
the DED of PEA-15 may contact the positively charged
ERK1/2 binding surface provided by helix G and the MAPK
insert. However, this region is not sufficient for PEA-15 bind-
ing, because a chimera containing subdomains X and XI of
ERK1/2 in p38 is unable to bind PEA-15 (data not shown).
This suggests that there are additional binding determinants
required for PEA-15 binding. The tail of PEA-15 is also es-
sential for ERK1/2 interaction and probably interacts with
ERK1/2 at a second site, which may be discontinuous with
the binding surface of the PEA-15 DED. The tail most likely
contacts a negatively charged and/or hydrophobic surface
given the deleterious effect of the PEA-15 mutations at
Lys122, Lys128, and Lys129 on ERK1/2 binding.
In summary, we have shown that the capacity of PEA-15 to
regulate integrin activation depends upon its binding to
ERK1/2. In addition, we identified ERK1/2 mutants that are
deficient for PEA-15 binding and prevent PEA-15 reversal of
integrin suppression. These observations suggest that rever-
sal of suppression is due to inhibition of an ERK1/2 function
rather than the acquisition of integrin-activating functions
by the PEA-15-ERK1/2 complex. Our data indicate that
ERK1/2 function is critical for H-Ras/Raf-1 suppression of
integrin activation. Whereas PEA-15 does not block ERK1/2
activation or its ability to phosphorylate several substrates
(10), it does change the subcellular localization of ERK1/2
(10). It is plausible to consider a mechanism in which ERK1/2
is unavailable to phosphorylate critical substrates required
for integrin suppression due to the interaction between
ERK1/2 and PEA-15. PEA-15 may delocalize ERK1/2, block-
ing access of ERK1/2 to a location necessary for phosphoryl-
ation of substrates required for integrin suppression. For
example, PEA-15 binding to ERK1/2 may remove ERK1/2
from a membrane-associated site such as focal adhesions (36)
or an association with arrestin (37). The results described
here suggest that ERK1/2 substrates at such sites will be
critical for the suppression of integrin activation.
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